$3.39 Billion is the total value of Perceptive Advisors's 99 reported holdings in Q1 2023. The portfolio turnover from Q4 2022 to Q1 2023 was 38.5% .
| Value | Shares | ↓ Weighting | ||||||
|---|---|---|---|---|---|---|---|---|
| FOLD | Buy | AMICUS THERAPEUTICS INC | $306,781,750 | -9.1% | 27,662,917 | +0.1% | 9.06% | -4.4% |
| RETA | New | REATA PHARMACEUTICALS INCcl a | $197,230,574 | – | 2,169,276 | +100.0% | 5.82% | – |
| Sell | AMYLYX PHARMACEUTICALS INC | $177,056,455 | -21.3% | 6,034,644 | -0.9% | 5.23% | -17.2% | |
| CERE | CEREVEL THERAPEUTICS HLDNG I | $158,851,021 | -22.7% | 6,511,727 | 0.0% | 4.69% | -18.7% | |
| MDGL | Sell | MADRIGAL PHARMACEUTICALS INC | $157,605,150 | -25.8% | 650,562 | -11.1% | 4.65% | -22.0% |
| RXDX | Buy | PROMETHEUS BIOSCIENCES INC | $136,585,520 | +2.4% | 1,272,694 | +4.9% | 4.03% | +7.7% |
| Buy | ARCELLX INC | $118,363,979 | +47.0% | 3,841,739 | +47.9% | 3.50% | +54.6% | |
| LIANBIOsponsored ads | $112,814,563 | +19.5% | 57,558,451 | 0.0% | 3.33% | +25.7% | ||
| ALDX | ALDEYRA THERAPEUTICS INC | $112,706,344 | +42.7% | 11,350,085 | 0.0% | 3.33% | +50.0% | |
| IOVA | Buy | IOVANCE BIOTHERAPEUTICS INC | $93,725,780 | +47.1% | 15,339,735 | +53.8% | 2.77% | +54.7% |
| INBX | Buy | INHIBRX INC | $68,222,277 | -16.4% | 3,615,383 | +9.1% | 2.01% | -12.2% |
| XENE | Sell | XENON PHARMACEUTICALS INC | $65,573,507 | -13.4% | 1,832,174 | -4.6% | 1.94% | -9.0% |
| BMRN | Buy | BIOMARIN PHARMACEUTICAL INC | $65,448,354 | +24.9% | 673,060 | +32.9% | 1.93% | +31.2% |
| TMCI | Buy | TREACE MED CONCEPTS INC | $61,520,278 | +37.5% | 2,442,250 | +25.5% | 1.82% | +44.5% |
| Buy | NUVALENT INC | $60,008,252 | -10.6% | 2,300,048 | +2.0% | 1.77% | -6.0% | |
| MRTX | Sell | MIRATI THERAPEUTICS INC | $58,526,302 | -41.1% | 1,574,134 | -28.2% | 1.73% | -38.0% |
| CRNX | Sell | CRINETICS PHARMACEUTICALS IN | $57,091,485 | -22.8% | 3,554,887 | -12.0% | 1.69% | -18.8% |
| VRNA | Sell | VERONA PHARMA PLCsponsored ads | $54,894,503 | -57.0% | 2,733,790 | -44.0% | 1.62% | -54.7% |
| SWTX | Sell | SPRINGWORKS THERAPEUTICS INC | $53,522,520 | -21.4% | 2,079,352 | -20.6% | 1.58% | -17.4% |
| New | ORCHESTRA BIOMED HLDGS INC | $44,584,883 | – | 2,278,226 | +100.0% | 1.32% | – | |
| VRDN | Buy | VIRIDIAN THERAPEUTICS INC | $44,173,660 | +23.9% | 1,736,386 | +42.3% | 1.30% | +30.3% |
| PCVX | VAXCYTE INC | $43,851,600 | -21.8% | 1,170,000 | 0.0% | 1.30% | -17.8% | |
| RAPT | Buy | RAPT THERAPEUTICS INC | $42,051,007 | +18.1% | 2,291,608 | +27.4% | 1.24% | +24.2% |
| SNY | New | SANOFIsponsored adr | $41,800,056 | – | 768,101 | +100.0% | 1.23% | – |
| ADMA | ADMA BIOLOGICS INC | $39,389,844 | -14.7% | 11,900,255 | 0.0% | 1.16% | -10.3% | |
| NTRA | Buy | NATERA INC | $39,264,521 | +651.9% | 707,214 | +444.0% | 1.16% | +688.4% |
| ACRIVON THERAPEUTICS INC | $38,169,718 | +10.2% | 3,007,858 | 0.0% | 1.13% | +15.8% | ||
| APLS | New | APELLIS PHARMACEUTICALS INC | $36,630,490 | – | 555,344 | +100.0% | 1.08% | – |
| MGTX | MEIRAGTX HLDGS PLC | $35,980,599 | -20.7% | 6,963,277 | 0.0% | 1.06% | -16.6% | |
| SRPT | Sell | SAREPTA THERAPEUTICS INC | $35,954,058 | -57.3% | 260,858 | -59.8% | 1.06% | -55.0% |
| BLU | Sell | BELLUS HEALTH INC NEW | $35,658,274 | -51.2% | 4,952,538 | -44.3% | 1.05% | -48.7% |
| CBAY | Buy | CYMABAY THERAPEUTICS INC | $34,036,384 | +665.7% | 3,903,255 | +450.5% | 1.00% | +704.0% |
| VRCA | VERRICA PHARMACEUTICALS INC | $32,753,389 | +136.4% | 5,038,983 | 0.0% | 0.97% | +148.6% | |
| RLAY | RELAY THERAPEUTICS INC | $32,002,807 | +10.2% | 1,943,097 | 0.0% | 0.94% | +16.0% | |
| ESTA | Sell | ESTABLISHMENT LABS HLDGS INC | $31,692,633 | -3.0% | 467,857 | -6.0% | 0.94% | +2.0% |
| BBIO | Buy | BRIDGEBIO PHARMA INC | $31,618,607 | +144.5% | 1,907,033 | +12.4% | 0.93% | +157.3% |
| Sell | ZYMEWORKS INC | $30,541,621 | -13.9% | 3,378,498 | -25.1% | 0.90% | -9.4% | |
| ASTRIA THERAPEUTICS INC | $29,119,844 | -10.7% | 2,189,462 | 0.0% | 0.86% | -6.0% | ||
| NAUT | NAUTILUS BIOTECHNOLOGY INC | $25,237,888 | +53.9% | 9,111,151 | 0.0% | 0.74% | +61.6% | |
| COGT | Sell | COGENT BIOSCIENCES INC | $24,626,276 | -33.6% | 2,282,324 | -28.8% | 0.73% | -30.2% |
| IMTX | IMMATICS N.V | $24,091,350 | -20.8% | 3,491,500 | 0.0% | 0.71% | -16.7% | |
| PTGX | New | PROTAGONIST THERAPEUTICS INC | $22,198,496 | – | 965,152 | +100.0% | 0.66% | – |
| OM | OUTSET MED INC | $20,045,457 | -28.7% | 1,089,427 | 0.0% | 0.59% | -25.1% | |
| IMVT | Buy | IMMUNOVANT INC | $20,036,718 | +652.6% | 1,291,858 | +761.2% | 0.59% | +689.3% |
| AKRO | Buy | AKERO THERAPEUTICS INC | $20,030,067 | +4.3% | 523,525 | +49.4% | 0.59% | +9.6% |
| Buy | ROIVANT SCIENCES LTD | $19,867,964 | +25.5% | 2,692,136 | +35.9% | 0.59% | +31.9% | |
| LYRA | LYRA THERAPEUTICS INC | $18,384,927 | -36.0% | 9,146,730 | 0.0% | 0.54% | -32.6% | |
| SOLID BIOSCIENCES INC | $16,570,722 | -11.9% | 3,495,933 | 0.0% | 0.49% | -7.4% | ||
| TARS | TARSUS PHARMACEUTICALS INC | $16,295,949 | -14.3% | 1,296,416 | 0.0% | 0.48% | -9.9% | |
| TERN | New | TERNS PHARMACEUTICALS INC | $15,984,000 | – | 1,350,000 | +100.0% | 0.47% | – |
| VBIV | VBI VACCINES INC CDA | $15,857,506 | -22.3% | 52,335,002 | 0.0% | 0.47% | -18.3% | |
| RCKT | Sell | ROCKET PHARMACEUTICALS INC | $14,864,249 | -29.6% | 867,732 | -19.5% | 0.44% | -26.0% |
| VKTX | New | VIKING THERAPEUTICS INC | $14,514,588 | – | 871,747 | +100.0% | 0.43% | – |
| MIRM | New | MIRUM PHARMACEUTICALS INC | $14,449,615 | – | 601,566 | +100.0% | 0.43% | – |
| RAIN | Sell | RAIN ONCOLOGY INC | $14,405,399 | -27.5% | 1,648,215 | -33.6% | 0.42% | -23.8% |
| CRY | ARTIVION INC | $14,224,766 | +8.1% | 1,085,860 | 0.0% | 0.42% | +13.5% | |
| AXGN | Buy | AXOGEN INC | $13,322,525 | -3.8% | 1,409,791 | +1.6% | 0.39% | +1.0% |
| ISRG | Buy | INTUITIVE SURGICAL INC | $12,773,500 | +20.3% | 50,000 | +25.0% | 0.38% | +26.5% |
| ISEE | Sell | IVERIC BIO INC | $12,165,000 | -3.3% | 500,000 | -14.9% | 0.36% | +1.7% |
| ATHA | ATHIRA PHARMA INC | $11,993,195 | -21.1% | 4,797,278 | 0.0% | 0.35% | -17.1% | |
| CYTEK BIOSCIENCES INC | $11,850,817 | -10.0% | 1,289,534 | 0.0% | 0.35% | -5.4% | ||
| PRTA | PROTHENA CORP PLC | $11,518,702 | -19.6% | 237,646 | 0.0% | 0.34% | -15.4% | |
| TCMD | New | TACTILE SYS TECHNOLOGY INC | $10,506,780 | – | 639,877 | +100.0% | 0.31% | – |
| FUSN | New | FUSION PHARMACEUTICALS INC | $10,404,959 | – | 2,759,936 | +100.0% | 0.31% | – |
| LRMR | Sell | LARIMAR THERAPEUTICS INC | $10,331,612 | -12.5% | 2,280,709 | -20.3% | 0.30% | -8.1% |
| NBIX | NEUROCRINE BIOSCIENCES INC | $10,127,061 | -15.3% | 100,050 | 0.0% | 0.30% | -11.0% | |
| BMEA | New | BIOMEA FUSION INC | $10,078,250 | – | 325,000 | +100.0% | 0.30% | – |
| MORF | Sell | MORPHIC HLDG INC | $9,663,581 | -0.5% | 256,737 | -29.3% | 0.28% | +4.4% |
| CMAX | Buy | CAREMAX INC | $9,548,027 | -16.4% | 3,576,040 | +14.3% | 0.28% | -12.1% |
| TYRA BIOSCIENCES INC | $7,945,056 | +111.4% | 494,403 | 0.0% | 0.24% | +121.7% | ||
| XBI | New | SPDR SER TRput | $7,621,000 | – | 100,000 | +100.0% | 0.22% | – |
| BLPH | New | BELLEROPHON THERAPEUTICS INC | $7,337,700 | – | 930,000 | +100.0% | 0.22% | – |
| HILLEVAX INC | $6,711,577 | -1.2% | 406,024 | 0.0% | 0.20% | +3.7% | ||
| CABA | Buy | CABALETTA BIO INC | $5,993,906 | +104.1% | 724,777 | +128.3% | 0.18% | +115.9% |
| AVDL | New | AVADEL PHARMACEUTICALS PLCsponsored adr | $5,404,400 | – | 590,000 | +100.0% | 0.16% | – |
| VERU | Sell | VERU INC | $4,985,926 | -88.0% | 4,298,212 | -45.3% | 0.15% | -87.4% |
| LABP | LANDOS BIOPHARMA INC | $4,431,234 | -40.4% | 14,869,915 | 0.0% | 0.13% | -37.3% | |
| XFOR | New | X4 PHARMACEUTICALS INC | $3,954,545 | – | 4,545,454 | +100.0% | 0.12% | – |
| OMIC | SINGULAR GENOMICS SYSTEMS IN | $3,971,553 | -39.8% | 3,282,275 | 0.0% | 0.12% | -36.8% | |
| SOMALOGIC INC | $3,825,000 | +1.6% | 1,500,000 | 0.0% | 0.11% | +6.6% | ||
| NBTX | NANOBIOTIXsponsored ads | $3,735,795 | -4.0% | 1,059,800 | 0.0% | 0.11% | +0.9% | |
| ENVVENO MEDICAL CORPORATION | $3,657,958 | -8.2% | 781,615 | 0.0% | 0.11% | -3.6% | ||
| VIR | New | VIR BIOTECHNOLOGY INC | $3,308,854 | – | 142,194 | +100.0% | 0.10% | – |
| HRMY | Sell | HARMONY BIOSCIENCES HLDGS IN | $3,265,000 | -85.6% | 100,000 | -75.7% | 0.10% | -84.9% |
| ADCT | New | ADC THERAPEUTICS SA | $2,916,820 | – | 1,495,805 | +100.0% | 0.09% | – |
| BLI | New | PHENOMEX INC | $2,907,473 | – | 2,506,442 | +100.0% | 0.09% | – |
| KRON | KRONOS BIO INC | $2,558,131 | -9.9% | 1,752,745 | 0.0% | 0.08% | -5.0% | |
| LPTX | LEAP THERAPEUTICS INC | $2,287,009 | -24.4% | 6,726,496 | 0.0% | 0.07% | -20.0% | |
| TVTX | TRAVERE THERAPEUTICS INC | $2,040,923 | +6.9% | 90,748 | 0.0% | 0.06% | +11.1% | |
| QTRX | New | QUANTERIX CORP | $1,465,100 | – | 130,000 | +100.0% | 0.04% | – |
| Sell | DARIOHEALTH CORP | $1,293,140 | -7.8% | 313,869 | -4.3% | 0.04% | -2.6% | |
| CLOV | CLOVER HEALTH INVESTMENTS CO | $1,267,650 | -9.1% | 1,500,000 | 0.0% | 0.04% | -5.1% | |
| New | ATHENEX INC | $1,032,909 | – | 776,623 | +100.0% | 0.03% | – | |
| TARA | PROTARA THERAPEUTICS INC | $907,860 | +16.8% | 290,051 | 0.0% | 0.03% | +22.7% | |
| PEAR THERAPEUTICS INC | $229,639 | -78.4% | 900,548 | 0.0% | 0.01% | -76.7% | ||
| MOTUS GI HLDGS INC | $87,641 | +15.9% | 90,027 | 0.0% | 0.00% | +50.0% | ||
| EQRX INC*w exp 12/17/202 | $43,125 | -35.7% | 250,000 | 0.0% | 0.00% | -50.0% | ||
| CMAXW | CAREMAX INC*w exp 06/08/202 | $28,908 | -7.7% | 60,000 | 0.0% | 0.00% | 0.0% | |
| SURROZEN INC*w exp 08/01/203 | $16,667 | +81.5% | 166,666 | 0.0% | 0.00% | – | ||
| NVRO | Exit | NEVRO CORP | $0 | – | -30,000 | -100.0% | -0.03% | – |
| ABOS | Exit | ACUMEN PHARMACEUTICALS INC | $0 | – | -347,450 | -100.0% | -0.05% | – |
| PRVA | Exit | PRIVIA HEALTH GROUP INC | $0 | – | -90,000 | -100.0% | -0.06% | – |
| ATNX | Exit | ATHENEX INC | $0 | – | -15,532,467 | -100.0% | -0.06% | – |
| Exit | PROCEPT BIOROBOTICS CORP | $0 | – | -64,537 | -100.0% | -0.08% | – | |
| PNT | Exit | POINT BIOPHARMA GLOBAL INC | $0 | – | -500,000 | -100.0% | -0.10% | – |
| SAVA | Exit | CASSAVA SCIENCES INCput | $0 | – | -150,000 | -100.0% | -0.12% | – |
| ACRS | Exit | ACLARIS THERAPEUTICS INC | $0 | – | -341,239 | -100.0% | -0.15% | – |
| PEN | Exit | PENUMBRA INC | $0 | – | -25,400 | -100.0% | -0.16% | – |
| Exit | ISOPLEXIS CORP | $0 | – | -4,095,498 | -100.0% | -0.18% | – | |
| SCPH | Exit | SCPHARMACEUTICALS INC | $0 | – | -952,380 | -100.0% | -0.19% | – |
| Exit | DICE THERAPEUTICS INC | $0 | – | -293,362 | -100.0% | -0.26% | – | |
| RVNC | Exit | REVANCE THERAPEUTICS INC | $0 | – | -729,097 | -100.0% | -0.38% | – |
| Exit | CINCOR PHARMA INC | $0 | – | -2,576,325 | -100.0% | -0.89% | – | |
| ALBO | Exit | ALBIREO PHARMA INC | $0 | – | -1,757,160 | -100.0% | -1.07% | – |
| MDGL | Exit | MADRIGAL PHARMACEUTICALS INCput | $0 | – | -300,000 | -100.0% | -2.44% | – |
| HZNP | Exit | HORIZON THERAPEUTICS PUB L | $0 | – | -960,000 | -100.0% | -3.07% | – |
Original filings
The following EDGAR filing(s) were analyzed to create this report:
- View 13F-HR/A filed 2023-05-16
About Perceptive Advisors
Perceptive Advisors is a New York-based hedge fund that specializes in healthcare investments. The company was founded in 1999 by Joseph Edelman, who serves as the CEO and Chief Investment Officer. Since its inception, Perceptive Advisors has become one of the most successful healthcare-focused hedge funds in the world, with over $5 billion in assets under management.
The company's investment strategy is based on a deep understanding of the healthcare industry and a focus on identifying promising companies with innovative products and technologies. Perceptive Advisors invests in a wide range of healthcare sectors, including biotechnology, pharmaceuticals, medical devices, and healthcare services.
One of the key factors behind Perceptive Advisors' success is its team of experienced professionals. In addition to Joseph Edelman, the company's leadership team includes Adam Stone, the COO, and Jeremy Goldberg, the Chief Scientific Officer. The team also includes a group of highly skilled analysts and researchers who are experts in their respective fields.
Perceptive Advisors has a strong track record of generating high returns for its investors. However, it is important to note that investing in hedge funds carries significant risks, and investors should carefully consider their investment objectives and risk tolerance before investing. As with any investment, it is important to conduct thorough research and seek the advice of a qualified financial advisor before making any investment decisions.
It's important to note that this information is for educational purposes only and has not been fact-checked. As with any investment, it's important to do your own research and consult with a financial advisor before making any investment decisions.
Top long-term holdings
| Name | Quarters owned | Latest quarter owned | Max weighting |
|---|---|---|---|
| NEUROCRINE BIOSCIENCES SHARES | 40 | Q1 2023 | 15.7% |
| AMICUS THERAPEUTICS SHARES | 37 | Q1 2023 | 14.0% |
| QUOTIENT TECHNOLOGY INC | 34 | Q3 2022 | 2.7% |
| ALDEYRA THERAPEUTICS SHARES | 33 | Q1 2023 | 3.3% |
| GLOBAL BLOOD THERAPEUTICS SHARES | 29 | Q3 2022 | 9.3% |
| RETROPHIN SHARES | 28 | Q3 2020 | 5.5% |
| DBV TECHNOLOGIES SA-SPON ADR | 28 | Q3 2021 | 1.8% |
| VBI VACCINES SHARES | 27 | Q1 2023 | 2.8% |
| ADMA BIOLOGICS SHARES | 27 | Q1 2023 | 1.4% |
| FERRARI SHARES | 26 | Q2 2022 | 0.0% |
View Perceptive Advisors's complete holdings history.
Latest significant ownerships (13-D/G)
| Filed | Shares | Percentage | |
|---|---|---|---|
| Landos Biopharma, Inc. | March 30, 2023 | 14,869,915 | 47.7% |
| Bellerophon Therapeutics, Inc. | March 14, 2023 | 930,000 | 8.9% |
| CymaBay Therapeutics, Inc. | March 10, 2023 | 5,278,962 | 5.6% |
| REATA PHARMACEUTICALS INC | March 07, 2023 | 2,083,799 | 6.5% |
| Acrivon Therapeutics, Inc. | February 14, 2023 | 3,007,858 | 14.4% |
| ADMA BIOLOGICS, INC. | February 14, 2023 | 11,900,255 | 5.4% |
| AGILE THERAPEUTICS INCSold out | February 14, 2023 | 0 | 0.0% |
| ALBIREO PHARMA, INC. | February 14, 2023 | 1,757,160 | 8.5% |
| Aldeyra Therapeutics, Inc. | February 14, 2023 | 11,350,085 | 19.4% |
| AMICUS THERAPEUTICS, INC. | February 14, 2023 | 27,642,917 | 9.8% |
View Perceptive Advisors's complete significant-ownership history.
Latest filings
| Type | Filed |
|---|---|
| 4 | 2023-06-02 |
| SC 13D/A | 2023-06-02 |
| 4 | 2023-06-01 |
| SC 13D/A | 2023-05-30 |
| 4 | 2023-05-26 |
| SC 13D/A | 2023-05-25 |
| 4 | 2023-05-23 |
| 3 | 2023-05-18 |
| SC 13D | 2023-05-18 |
| 13F-HR/A | 2023-05-16 |
View Perceptive Advisors's complete filings history.
All filings
- Holdings (13F-HR)
- Significant ownership (13-D/G)
- Insider transactions (4, 5, 6)
- Events (8-K)
- Shareholder votes (proxy)
View complete filings history.